SCHEMBL4154357

SCHEMBL4154357

CCOC(=O)c1cc(C2=C(c3cc(Cl)cnc3OCc3ccccc3)CCC2)ccc1C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 8/20 0.46
CYP2C9 P11712 3/20 0.46
CNR1 P21554 2/20 0.40
MEN1 O00255 1/20 0.39
HSP90AA1 P07900 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
NMT1 P30419 1/20 0.39
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163577 0.92 PTGER1 (0.48) PTGER1CYP2C9CNR1MEN1HSP90AA1
SCHEMBL4163796 0.91 PTGER1 (0.53) PTGER1CYP2C9CNR1MEN1KMT2A
SCHEMBL4162769 0.91 PTGER1 (0.51) PTGER1CYP2C9CNR1
SCHEMBL13697416 0.86 CNR1 (0.40) PTGER1CYP2C9CNR1MEN1KMT2A
SCHEMBL5620038 0.86 PTGER1 (0.64) PTGER1CYP2C9
SCHEMBL4439898 0.85 PTGER1 (0.54) PTGER1CYP2C9CNR1
SCHEMBL4150169 0.83 PTGER1 (0.44) PTGER1CYP2C9CNR1MEN1KMT2A
SCHEMBL4146593 0.83 PTGER1 (0.46) PTGER1CYP2C9CNR1MAPT
SCHEMBL13696726 0.83 PTGER1 (0.40) PTGER1CYP2C9MEN1KMT2AMAPT
SCHEMBL4163426 0.83 PTGER1 (0.62) PTGER1CYP2C9CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
US-20090227591-A1 Cyclopentene compounds GLAXO GROUP LIMITED (GB) 2009-09-10 US disclosed
EP-1670763-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-06-21 EP disclosed
WO-2005037793-A1 CYCLOPENTENE COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227591-A1 Cyclopentene compounds C1R, CYP1B1, ADORA2B PTGER1 246/4885CYP2C9 5/4885CNR1 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.